Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study
Abstract Background The current study evaluated the long-term (52 week) safety and impact on symptom measures of lurasidone (with or without lithium or valproate) for the treatment of bipolar I disorder in Japanese patients. Methods Bipolar patients for this open-label flexibly dosed lurasidone (20–...
Main Authors: | Teruhiko Higuchi, Tadafumi Kato, Mari Miyajima, Kei Watabe, Takahiro Masuda, Katsuhiko Hagi, Jun Ishigooka |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2021-08-01
|
Series: | International Journal of Bipolar Disorders |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40345-021-00230-8 |
Similar Items
-
Lurasidone-induced tardive dyskinesia
by: Shreyas Shrikant Pendharkar, et al.
Published: (2022-01-01) -
Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies
by: Isabella Costamagna, et al.
Published: (2021-01-01) -
Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
by: Iyo M, et al.
Published: (2021-08-01) -
Long-term safety and effectiveness of lurasidone in adolescents and young adults with schizophrenia: pooled post hoc analyses of two 12-month extension studies
by: Fabrizio Calisti, et al.
Published: (2024-07-01) -
A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression
by: Taro Kishi, et al.
Published: (2023-03-01)